Floatz logo

Bezuclastinib

Aggressive Systemic Mastocytosis

Cogent Biosciences, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Aggressive Systemic Mastocytosis cohort.

Asset / SponsorPhaseRating
Avapritinib
Blueprint Medicines Corporation
Phase 2BB
Brentuximab Vedotin
Jason Robert Gotlib
Phase 2B
Midostaurin
Jason Robert Gotlib
Phase 2B
Ibrutinib
Jason Robert Gotlib
Phase 2CCC
mgd024
MacroGenics
Phase 1NR

Same molecule, other indications

Bezuclastinib is also rated in:

gastrointestinal stromal tumorActive
BB
Indicative · Phase 3
66 / 100
View asset →
metastatic malignant neoplasmActive
CCC
Indicative · Phase 3
54 / 100
View asset →
systemic mastocytosisActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →